GPIHBP1 Is Responsible for the Entry of Lipoprotein Lipase into Capillaries  by Davies, Brandon S.J. et al.
Cell Metabolism
ArticleGPIHBP1 Is Responsible for the Entry
of Lipoprotein Lipase into Capillaries
Brandon S.J. Davies,1 Anne P. Beigneux,1 Richard H. Barnes II,1 Yiping Tu,1 Peter Gin,1 Michael M. Weinstein,2
Chika Nobumori,1 Rakel Nyre´n,3 Ira Goldberg,4 Gunilla Olivecrona,3 Andre´ Bensadoun,5 Stephen G. Young,1,2
and Loren G. Fong1,*
1Department of Medicine
2Department of Human Genetics
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
3Department of Medical Biosciences/Physiological Chemistry, Umea˚ University, S-901 87 Umea˚, Sweden
4Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
5Division of Nutritional Science, Cornell University, Ithaca, NY 14853, USA
*Correspondence: lfong@mednet.ucla.edu
DOI 10.1016/j.cmet.2010.04.016SUMMARY
The lipolytic processing of triglyceride-rich lipopro-
teins by lipoprotein lipase (LPL) is the central event
in plasma lipid metabolism, providing lipids for
storage in adipose tissue and fuel for vital organs
such as the heart. LPL is synthesized and secreted
by myocytes and adipocytes, but then finds its way
into the lumen of capillaries, where it hydrolyzes lipo-
protein triglycerides. The mechanism by which LPL
reaches the lumen of capillaries has remained an
unresolved problem of plasma lipid metabolism.
Here, we show that GPIHBP1 is responsible for the
transport of LPL into capillaries. InGpihbp1-deficient
mice, LPL is mislocalized to the interstitial spaces
surrounding myocytes and adipocytes. Also, we
show that GPIHBP1 is located at the basolateral
surface of capillary endothelial cells and actively
transports LPL across endothelial cells. Our experi-
ments define the function of GPIHBP1 in triglyceride
metabolism and provide a mechanism for the trans-
port of LPL into capillaries.
INTRODUCTION
The lipolytic processing of triglyceride-rich lipoproteins by lipo-
protein lipase (LPL) provides fuel to vital tissues, such as the
heart, and lipids for storage in adipose tissue (Olivecrona and
Olivecrona, 2009; Wang and Eckel, 2009). Lipolysis also leads
to the production of atherogenic remnant lipoproteins (e.g.,
low-density lipoproteins) and provides lipids for the formation
of high-density lipoprotein particles. LPL is a homodimer, and
its activity requires a protein cofactor, apolipoprotein (apo-)
CII, which is carried within lipoproteins. A deficiency of LPL or
apo-CII causes familial chylomicronemia, a severe form of hy-
pertriglyceridemia (Brunzell and Deeb, 2001).
The lipolysis of lipoproteins by LPL occurs at the surface of
capillaries, mainly in skeletal muscle, heart, and adipose tissue
(Havel and Kane, 2001; Olivecrona and Olivecrona, 2009;42 Cell Metabolism 12, 42–52, July 7, 2010 ª2010 Elsevier Inc.Wang and Eckel, 2009). Remarkably, however, LPL is not ex-
pressed by capillary endothelial cells. Instead, LPL is produced
by the parenchymal cells, myocytes and adipocytes, and
secreted into the surrounding interstitial spaces. From there,
LPL finds its way into the lumen of capillaries. An earlier study
suggested that the VLDL receptor (VLDLR) might be involved
in the transport of LPL across capillaries (Obunike et al., 2001),
but the significance of that finding is uncertain because VLDLR
deficiency does not lead to hypertriglyceridemia (Frykman
et al., 1995). No further progress has been made on this issue,
and the mechanism for the entry of LPL into capillaries remains
unknown.
Recently, Beigneux et al. (2007) identified a critical role for
GPIHBP1 in lipolysis. GPIHBP1 is a glycosylphosphatidylinosi-
tol (GPI)-anchored glycoprotein of the lymphocyte antigen 6
(Ly6) family and is expressed in endothelial cells. Cell transfec-
tion studies revealed that GPIHBP1 binds LPL and that this
binding could be blocked with heparin. Gpihbp1-deficient
mice develop severe hypertriglyceridemia, even on a chow
diet, with plasma triglyceride levels >3000 mg/dl. These find-
ings prompted Beigneux et al. (2007) to speculate that
GPIHBP1 could serve as a binding site for LPL in capillaries;
however, the precise role of this molecule in lipolysis was not
elucidated.
In this study, we examined the role of GPIHBP1 in proper local-
ization of LPL within capillaries and tested whether GPIHBP1 is
the critical molecule in shuttling LPL from the interstitial spaces
to the lumenal surface of capillary endothelial cells.RESULTS
GPIHBP1 Is Present on the Lumenal Face of Capillaries
Early immunohistochemical studies with a rabbit antiserum
against mouse GPIHBP1 revealed that GPIHBP1 is found on
capillaries of heart, skeletal muscle, and adipose tissue
(Beigneux et al., 2007). In this study, to determine if GPIHBP1
is present on the lumenal surface of capillaries, wild-type and
Gpihbp1-deficient (Gpihbp1/) mice were given an intravenous
injection of an Alexa 555-labeled GPIHBP1-specific monoclonal
antibody (antibody 11A12) and an antibody against CD31 (an
endothelial cell marker). Five minutes later, the mice were
Figure 1. GPIHBP1 Is Locatedwithin the Lumen of Capillaries
(A) Confocal images of white adipose tissue revealing GPIHBP1 in the
capillaries of wild-type but not Gpihbp1/ mice. Mice were injected
intravenously with Alexa 555-labeled anti-GPIHBP1 (red) and hamster
anti-CD31 antibodies and then perfused extensively with PBS. Fixed
adipose explants were stained with FITC-labeled anti-hamster anti-
bodies (green) and BODIPY to label adipocytes (blue). The scale bar
represents a distance of 100 mm.
(B) Confocal images of heart tissue from the same antibody-injected
wild-type and Gpihbp1/ mice showing GPIHBP1 staining in the
capillaries of wild-type but notGpihbp1/mice. Tissues were stained
with an antibody against b-dystroglycan (magenta), a plasma
membrane protein of myocytes, to outline myocytes. The scale bar
represents a distance of 100 mm. (See also Figure S1.)
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LPL Transport into Capillarieseuthanized and their tissues were perfused extensively with
PBS. In the adipose tissue of wild-type mice, antibody 11A12
binding was restricted to capillaries, colocalizing with antibodies
to CD31. In the adipose tissue of Gpihbp1/ mice, CD31 was
found in capillaries, but GPIHBP1 was absent (Figure 1A). Simi-
larly, GPIHBP1 and CD31 colocalized in the capillaries of the
heart in wild-type mice, but only CD31 was detected in
Gpihbp1/ mice (Figure 1B). Interestingly, GPIHBP1 was
confined to capillaries surrounding myocytes, whereas CD31
was found in both capillaries and larger vessels (Figure 1B).
GPIHBP1 was not detectable in the capillaries of the brain
(Figure S1).
GPIHBP1 and LPL Normally Colocalize in Capillaries
Because expression of GPIHBP1 in Chinese hamster ovary
(CHO) cells confers the ability to bind LPL (Beigneux et al.,
2007, 2009a, 2009b; Gin et al., 2008), we hypothesized that at
least some of the LPL in mouse tissues might colocalize with
GPIHBP1 in capillaries. To test this hypothesis, we performed
immunohistochemistry with a chicken antibody against bovine
LPL and a goat antibody against a recombinant mouse LPL
fragment (Olivecrona and Bengtsson, 1983; Weinstein et al.,
2008). Both antibodies identified a single 52 kDa protein in
CHO cells expressing V5-tagged mouse LPL (Figures S2A
and S2B). By immunofluorescence, both antibodies bound
mouse LPL-transfected CHO cells (Figure S2C). When Lpl-
transfected and Gpihbp1-transfected CHO cells were mixed,
immunofluorescence microscopy revealed that LPL and
GPIHBP1 colocalized on the surface of cells (i.e., the LPL
secreted by LPL-expressing cells bound avidly to Gpihbp1-
transfected cells) (Figure S2D), showing that both antibodiesCellbind LPL when it is also bound to GPIHBP1. Both anti-
bodies detected mouse LPL in the heart of wild-type
mice, but neither detected LPL (human or mouse) in
the hearts of Lpl/ mice that had been rescued with
a muscle-specific human Lpl transgene (Weinstock
et al., 1997) (Figures S2E and S2F).
By immunofluorescence microscopy, most of the LPL
in brown adipose tissue was located in capillary endothe-
lial cells, colocalizing with GPIHBP1 (Figures 2A and 2B).
Both LPL and GPIHBP1 were identified in capillaries;
neither was found in larger blood vessels (Figure 2B).
The capillaries of the heart, all positive for GPIHBP1,
also stained for LPL; this capillary staining was intenseand was visible above the less-intense LPL staining in myocytes
(Figures S2E, S2F, and 2C).
LPL Is Mislocalized Away from Capillaries
in Gpihbp1/ Mice
To determine if GPIHBP1 plays a role in the targeting of LPL to
capillaries, we examined the localization of LPL in the tissues
of Gpihbp1/ mice. The LPL in brown adipose tissue of
Gpihbp1/ mice surrounded adipocytes, colocalizing with the
extracellular matrix protein collagen IV (Figure 3A). Similar mis-
localization was observed in both heart and skeletal muscle of
Gpihbp1/ mice; the LPL surrounded myocytes, colocalizing
with b-dystroglycan (a plasma membrane protein of myocytes)
(Figures 3B, 3C, and S3A) or laminin, a basement membrane
protein surrounding myocytes (Figures S3B and S3C).
GPIHBP1-Mediated Transport across Endothelial Cells
The mislocalization of LPL in Gpihbp1/ mice prompted us to
consider the possibility that GPIHBP1 plays a role in the transport
of LPL across capillary endothelial cells. We reasoned that the
involvementofGPIHBP1 in transportwould require thatGPIHBP1
be present on the basolateral surface of cells (in proximity to the
LPL secreted by adipocytes and myocytes). To determine if
some GPIHBP1 is present on the basolateral surface of cells,
we examined rat heart microvessel endothelial cells (RHMVECs)
that expressed an S-protein-tagged version of GPIHBP1. We
usedRHMVECs that hadbeen transducedwith amouseGpihbp1
lentivirus because the expression of Gpihbp1 from the endoge-
nousgene is nearly undetectablewithinadayafterplatingprimary
cells (Davies et al., 2008). We compared Gpihbp1 expression
levels in transduced RHMVECs with Gpihbp1 expression levelsMetabolism 12, 42–52, July 7, 2010 ª2010 Elsevier Inc. 43
Figure 2. GPIHBP1 and LPL Colocalize
within Capillaries
(A and B) Confocal images showing the binding of
GPIHBP1-, LPL-, and CD31-specific antibodies to
brown adipose tissue (BAT) from a wild-type
mouse. Images were taken with a 633 objective:
close-up (A, scale bar represents distance of
50 mm) and wide-field (B, scale bar represents
distance of 100 mm).
(C) Confocal images showing the binding of
GPIHBP1-, LPL-, and b-dystroglycan-specific
antibodies to heart tissue from a wild-type mouse.
The scale bar represents a distance of 25 mm.
(See also Figure S2.)
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LPL Transport into Capillariesin endothelial cells of mouse tissues by quantitative RT-PCR,
normalizing the data toCd31 (expressed only in endothelial cells).
Gpihbp1 expression in lentivirus-transduced RHMVECs was
20% of endothelial cells in brown adipose tissue and 40% of
endothelial cells in the heart (Figure 4A).
The Gpihbp1- and empty vector-transduced RHMVECs were
grown on polyethylene terephthalate filters (1 mm pore size),
which make it possible to expose the basolateral surface of cells
to one medium and the apical surface to another. The RHMVECs
formed tight monolayers, as judged by electrical resistance
measurements and the ability of the monolayer to prevent the
flow of medium from one chamber to the other. To determine if
GPIHBP1 is present at both the apical and basolateral surfaces
of endothelial cells, phosphatidylinositol-specific phospholipase
C (PIPLC) was added to the apical or the basolateral chamber,
and the release of GPIHBP1 into the medium was monitored
with western blots. PIPLC released GPIHBP1 from both the ba-
solateral and apical surface of cells (Figure 4B). One possible
explanation for the lower amount of GPIHBP1 release from the
basolateral surface was that the access of PIPLC to the basolat-
eral surface of cells may have been limited (pores represent only
4% of the surface area of the filters).
GPIHBP1 localization in endothelial cell monolayers was
also examined by microscopy. For these experiments, Alexa
555-labeled antibody 11A12 was added to both the apical and
basolateral chambers. By confocal microscopy, GPIHBP1 was
detected in the uppermost and middle optical slices of endothe-
lial cells. When the most inferior slices of the cells were exam-
ined, small patches of intense GPIHBP1 staining were observed,
corresponding to regions of the plasma membrane adjacent to
the filter’s pores (i.e., the regions in direct contact with the anti-
body in the medium) (Figure 4C).44 Cell Metabolism 12, 42–52, July 7, 2010 ª2010 Elsevier Inc.To test whether GPIHBP1 could
traverse endothelial cells, we measured
its ability to transport a specific anti-
GPIHBP1 monoclonal antibody (11A12)
from the basolateral media to the apical
media. RHMVECs were grown on filters
(Figure 4D), and IRDye800-conjugated
antibody 11A12 and an IRDye680-conju-
gated irrelevant antibody (a donkey anti-
goat IgG) were added to the basolateral
chamber. After a 3 hr incubation at
37C, the apical surface of the cells was
incubated with PIPLC, releasing GPIHBP1 along with any bound
antibody into the medium. The amount of each antibody in the
apical medium was assessed by dot blot with an Odyssey
infrared scanner. Neither the GPIHBP1- nor the vector-trans-
duced cells transported the irrelevant antibody into the upper
chamber efficiently, but the GPIHBP1-transduced cells trans-
ported antibody 11A12 into the upper chamber (Figures 4E
and 4F). The transport of antibody 11A12 required the presence
of GPIHBP1 at the basolateral surface of cells; when basolateral
GPIHBP1 was clipped off with PIPLC, transport of the antibody
to the apical chamber was abolished (Figure 4G).
GPIHBP1 Transports LPL across Endothelial Cells
To test whether GPIHBP1 could transport LPL across endothe-
lial cell monolayers, human LPL (hLPL) was added to the baso-
lateral side of Gpihbp1-transduced RHMVECs. After a 1 hr
incubation at 37C, the LPL content of the apical medium was
assessed by dot blot. In some studies, cells were treated with
heparin to release any surface-bound LPL into the medium.
Even in the absence of heparin, more LPL was present in the
apical medium of Gpihbp1-transduced cells than in vector-
transduced cells (Figure 5A).When heparin was added to release
cell-surface LPL, the differences in the content of LPL in the
apical medium were more pronounced (Figure 5A). In control
experiments, we found that bovine serum albumin (BSA) trans-
port was not affected by the expression of GPIHBP1 or by the
addition of heparin to the apical surface of cells (Figure S4A).
We also found that the amount of LPL transported to the apical
surface of cells was dependent on the amount of LPL in the
basolateral medium (Figures S4B and S4C). Finally, LPL trans-
port occurredwhenGpihbp1-transduced bovine aortic endothe-
lial cells were used instead of RHMVECs (Figures S4D and S4E).
Figure 3. Mislocalization of LPL in
Gpihbp1/ Mice
(A) Confocal microscopy showing the binding
of GPIHBP1-, LPL-, and collagen IV-specific
antibodies to brown adipose tissue (BAT) from
wild-type and Gpihbp1/ mice. The scale bars
represent a distance of 100 mm.
(B and C) Confocal microscopy showing the
binding of CD31-, LPL-, and b-dystroglycan-
specific antibodies to heart (B) and skeletal muscle
(C) of wild-type and Gpihbp1/ mice. The scale
bars represent a distance of 100 mm (skeletal
muscle) or 50 mm (heart).
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LPL Transport into CapillariesWe also assessed transport of a highly purified bovine LPL
preparation acrossGpihbp1- and vector-transduced RHMVECs.
Once again, LPL was placed in the basolateral medium; after 1
hr, heparin was added to the apical chamber, and the LPL
concentration in the apical medium was measured with an
ELISA. LPL transport to the apical surface of cells was absent
in vector-transduced cells but was easily detectable with
Gpihbp1-transduced cells (Figure 5B).
When the LPL transport studies were carried out at 4C,
GPIHBP1-specific transport of LPL was blocked (Figure 5C). At
37C, adding heparin or PIPLC to the basolateral chamber
largely blocked the transport of LPL (Figure 5D).
Gin et al. (2008) showed that the acidic domain of GPIHBP1 is
required for LPL binding. We predicted that a mutant GPIHBP1
lacking the acidic domain would be unable to transport LPL but
would retain the ability to transport antibody 11A12 (which binds
to an epitope outside of the acidic domain) (Beigneux et al.,
2009b). To test this prediction, we generated a mutant GPIHBP1Cell Metabolism 12,lentivirus inwhich all of the aspartates and
glutamates in the acidic domain were
replaced with alanine (D,E(24–48)A).
Endothelial cells transduced with this
mutant GPIHBP1 transported antibody
11A12 normally (Figure 5E), but their
ability to transport LPL was markedly
impaired (Figure 5F).
GPIHBP1 Can Function as
a Transporter In Vivo
We sought evidence that GPIHBP1 was
present on both the basolateral and
apical (lumenal) surfaces of capillary
endothelial cells in vivo and that it could
function as a transporter. To assess the
presence of GPIHBP1 on the apical and
basolateral surfaces of capillary endothe-
lial cells, we examined cross-sections of
capillaries in brown adipose tissue by
confocal microscopy. The basolateral
and apical surfaces of endothelial cells
could be easily resolved in cross-
sections of capillaries containing a cell
nucleus. In those sections, GPIHBP1
was present on both the apical and baso-lateral surfaces. The amount of GPIHBP1 on the basolateral and
apical surfaces of endothelial cells was roughly equivalent
(Figure 6A).
To determine if GPIHBP1 could function as a transporter
in vivo, we performed an intramuscular injection of one quadri-
ceps muscle in wild-type and Gpihbp1/ mice with the
GPIHBP1-specific monoclonal antibody 11A12, along with
nonimmune rabbit IgG. After 30 min, the mice were injected
intravenously with fluorescently labeled secondary antibodies,
with the goal of ascertaining whether either antibody had been
taken up by endothelial cells and transported into the lumen of
capillaries. Three minutes after the intravenous injection of the
fluorescent antibodies, the mice were extensively perfused
with PBS, and tissues were fixed in situ with paraformalde-
hyde (PFA). Frozen sections were prepared and stained
with an antibody against CD31 to identify endothelial cells. In
wild-type mice, the fluorescent anti-rat antibody was detected
exclusively in capillaries, colocalizing with CD31. No such42–52, July 7, 2010 ª2010 Elsevier Inc. 45
Figure 4. GPIHBP1 Is Present at the Basolateral andApical Surfaces of Cultured Endothelial Cells and Transports aGPIHBP1-SpecificMono-
clonal Antibody across Cells
(A)Gpihbp1 expression levels in lentivirus-transduced RHMVECs andmouse heart, skeletal muscle, brown adipose tissue (BAT), andwhite adipose tissue (WAT).
Gpihbp1 expression levels were measured by quantitative RT-PCR and normalized to Cd31 (mean ±SEM).
(B) Release of GPIHBP1 by PIPLC from apical and basolateral surfaces ofGpihbp1-transduced RHMVEC monolayers grown on filters. After incubating the cells
with PIPLC (5 U/ml) for 1.5 hr, the medium was harvested from the apical and basolateral chambers, precipitated with 10% TCA, and size fractionated by
SDS-PAGE. Western blots were performed with antibody 11A12.
(C) Confocal microscopy showing the binding of antibody 11A12 to Gpihbp1-transduced RHMVECs. Alexa 555-labeled antibody 11A12 was added to both the
apical and basolateral chambers, and images of optical sections were obtained with a confocal microscope (633 objective) near the top, middle, and bottom of
the cells. Green lines outline individual cells.
(D) Schematic of the transport assay. RHMVECs were grown on filters (1 mm pore size) until they formed a tight monolayer. Antibodies were added to the
basolateral chamber and cells were incubated at 37C. After the incubation, PIPLC was added to the apical chamber to release GPIHBP1; media from the apical
and basolateral chambers were collected and analyzed.
(E and F) Dot blots demonstrating the transport of antibody 11A12 from the basolateral to the apical surface of Gpihbp1-transduced RHMVEC monolayers.
IRDye800-labeled antibody 11A12 (green) and an IRDye680-labeled anti-goat IgG control antibody (red) were added to the basolateral chamber and incubated
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Figure 5. Transport of LPL across Endothe-
lial Cell Monolayers
(A) Dot blot analysis demonstrating the transport
of V5-tagged human LPL (hLPL) from the basolat-
eral to the apical chamber by Gpihbp1-trans-
duced RHMVECs. After adding LPL to the basolat-
eral chamber and incubating for 1 hr at 37C,
either heparin (100 U/ml) or PBS was added to
the apical chamber, and the apical medium was
dot blotted with an antibody against the V5 tag
and quantified with the Odyssey scanner. Bar
graph shows the fold change (mean ±SEM)
compared to vector-transduced cells from four
independent experiments.
(B) Transport of bovine LPL from the basolateral to
the apical chamber by Gpihbp1- or vector-trans-
duced RHMVECs grown on filters. After adding
bovine LPL to the basolateral chamber and incu-
bating for 1 hr at 37C, the apical surface of cells
was treated with heparin (100 U/ml) or PBS for
15 min at room temperature. The apical medium
was collected, and the LPL concentration was
determined with an ELISA. The bar graph shows
the percentage of total LPL detected in the apical
media (mean ±SEM). No LPL was detected in the
samples marked n.d.
(C) GPIHBP1-mediated LPL transport across
endothelial cells at 4C and 37C. After adding
V5-tagged hLPL to the basolateral chamber,
Gpihbp1-transduced RHMVECs were incubated
for 1 hr at 4C or 37C. Heparin was then added
to the apical chamber (100 U/ml; 15 min at 4C),
and the amount of LPL in the apical medium was
assessed by dot blot with an antibody against
the V5 tag. The blot was scanned and quantified
with the Odyssey scanner. Bar graph shows the
fold change (mean ±SEM) compared to vector-
transduced cells incubated at 37C.
(D) Ability of PIPLC or heparin in the basolateral
medium to block GPIHBP1-mediated transport
of the V5-tagged hLPL from the basolateral to the apical medium of RHMVECs. After adding LPL and either heparin (100 U/ml) or PIPLC (2.5 U/ml) to the baso-
lateral chamber, the cells were incubated for 1 hr at 37C. Heparin was added to the apical chamber (100 U/ml; 15 min at room temperature), and the amount of
LPL in the apical medium was then assessed by dot blotting with an antibody against the V5 tag. The blot was scanned and quantified with the Odyssey scanner.
Bar graph shows the fold change (mean ±SEM) compared to vector-transduced cells.
(E) Dot blot analysis of antibody 11A12 transport in RHMVECs transduced with wild-type or mutant (D,E(24–48)A) GPIHBP1. IRDye800-labeled antibody 11A12
was added to the basolateral chamber and incubated for 1 hr at 37C. The apical surface was then treated with PIPLC (1 U/ml; 30 min) or PBS; the apical medium
was dot blotted, scanned, and analyzed with the Odyssey scanner. Bar graph shows fold change (mean ±SEM) compared to vector-transduced control cells.
(F) Dot blot analysis of LPL transport in RHMVECs transduced with either wild-type or mutant (D,E(24–48)A) GPIHBP1. After adding LPL to the basolateral
chamber and incubating for 1 hr at 37C, the apical surface was treated with PIPLC (2.5 U/ml) or PBS (30 min at 37C). The apical medium was then dot blotted
with an antibody against the V5 tag, and the signal was quantified with the Odyssey scanner. Bar graph shows the fold change (mean ±SEM) compared to vector-
transduced control cells. (See also Figure S4.)
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LPL Transport into Capillariesstaining was observed in Gpihbp1/mice (Figure 6B). The fluo-
rescently labeled antibody against rabbit IgGwas not detected in
either wild-type orGpihbp1/ capillaries (Figure 6B). Also, in the
wild-type mice, no staining of capillaries was observed in the
contralateral (noninjected) quadriceps muscle. As expected,for 3 hr at 37C. The apical surface was treated with PIPLC (1 U/ml; 30 min) or
quantified with the Odyssey scanner. Bar graph in (F) shows the fold change (mean
experiments.
(G) Analysis of the ability of basolateral PIPLC to block the transport of antibody
11A12 and IRDye680-labeled anti-goat IgG antibody were added to the basolat
1.5 hr at 37C. The apical surface was treated with PIPLC (1 U/ml; 30 min), and t
scanner. The bar graph shows the fold change (mean ±SEM) compared to untrewhen adjacent sections of skeletal muscle were directly stained
with fluorescently labeled anti-rat and anti-rabbit secondary
antibodies, we observed abundant amounts of antibody 11A12
and the rabbit IgG in the interstitial spaces (surrounding the my-
ocytes of wild-type and Gpihbp1/ muscle) (Figure 6C).PBS, and both apical and basolateral media were dot blotted, scanned, and
±SEM) compared to untreated vector-transduced cells from four independent
11A12 from the basolateral to the apical chamber. IRDye800-labeled antibody
eral chamber in the presence or absence of PIPLC (1 U/ml) and incubated for
he apical medium was dot blotted, scanned, and quantified with the Odyssey
ated vector-transduced cells.
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Figure 6. GPIHBP1 Is Present at Both the
Basolateral and Apical Surfaces of Endo-
thelial Cells In Vivo and Transports Mono-
clonal Antibody 11A12 across Capillary
Endothelial Cells
(A) Confocal microscopy showing the binding of
GPIHBP1- and CD31-specific antibodies to brown
adipose tissue of a wild-type mouse. Images were
taken with a 1003 objective without optical zoom
(low magnification) or with 43 optical zoom (high
magnification). To visualize both the apical and ba-
solateral surfaces of capillaries, cross-sections of
capillaries that cut through an endothelial cell
nucleus (blue) were identified (boxed areas) and
viewed at high magnification. Both GPIHBP1
(red) and CD31 (green) were expressed at the
apical (arrowheads) and basolateral (arrows)
surfaces of endothelial cells. The scale bar repre-
sents a distance of 2.5 mm.
(B) Microscopy showing the transport of antibody
11A12 from the interstitial spaces to the lumens of
capillaries of skeletal muscle. One quadriceps
muscle of a wild-type and a Gpihbp1/ mouse
was injected with 10 ml of normal saline containing
15mgeachof the ratGPIHBP1-specificmonoclonal
antibody 11A12 and nonimmune rabbit IgG. After
30 min, the mice were injected intravenously with
200 mg each of fluorescent-labeled goat anti-rabbit
IgG (pseudo-color cyan) and fluorescent-labeled
goat anti-rat IgG (red). Three minutes later, the
mice were extensively perfused with PBS and
tissues were fixed in situ with 3% PFA. Frozen
sections were prepared and stained with anti-
bodies against CD31 (green) to identify endothelial
cells and DAPI to identify nuclei. In wild-type mice,
fluorescent-labeled anti-rat antibody was easily
detectable within the capillaries of the injected
muscle, whereas no staining was present in the
skeletal muscle of Gpihbp1/ mice. The scale
bar represents a distance of 100 mm.
(C) Microscopy showing the presence of injected
antibodies in the interstitial spaces of skeletal
muscle. Frozen sections adjacent to the sections
shown in (B) were stained with fluorescent-labeled
anti-rat antibody (red) and anti-rabbit antibody
(pseudo-color cyan) to document the presence of
antibody 11A12 and rabbit IgGwithin the interstitial
spaces of the injected muscles. As expected, anti-
body 11A12 and rabbit IgG were present in both
wild-type and Gpihbp1/ mice. The scale bar
represents a distance of 100 mm.
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LPL Transport into CapillariesAbsence of LPL at the Lumenal Surface of Capillaries
in Gpihbp1/ Mice
The fact that GPHBP1 functions as a transporter in vivo
combined with the fact that LPL is mislocalized in Gpihbp1/
mice made us suspect that LPL would be absent from the
lumenal surface of capillaries of Gpihbp1/ mice. To address
this issue in a direct fashion, wild-type and Gpihbp1/ mice
were injected intravenously with an anti-LPL antibody as well
as FITC-labeled tomato lectin (which binds to the lumenal
surface of capillaries). Five minutes later, mice were euthanized,
their tissues were extensively perfused with PBS, and the heart
was harvested. In the heart of wild-type mice, LPL was visible
within capillaries, but LPL was nearly undetectable in the capil-
laries of Gpihbp1/ mice (Figure 7A).48 Cell Metabolism 12, 42–52, July 7, 2010 ª2010 Elsevier Inc.We also examined LPL localization in Gpihbp1/ mice with
confocal microscopy of cross-sections of capillaries in brown
adipose tissue of wild-type and Gpihbp1/ mice. As ex-
pected, GPIHBP1 was present on both the lumenal and ablu-
menal surfaces of endothelial cells in wild-type mice
(Figure 7B). Of note, LPL was present on both the lumenal
and ablumenal surfaces of capillaries in wild-type mice, but
was absent from the lumen in Gpihbp1/ mice (Figures 7B
and S5). These findings are consistent with the ability of
GPIHBP1 to serve as a transporter from the basolateral to
the apical surfaces of endothelial cells (Figures 4–6) and
strongly support the idea that GPIHBP1 is the critical molecule
for shuttling LPL from the interstitial spaces into the capillary
lumen.
Figure 7. LPL Is Absent from Capillary Lumens in Gpihbp1/ Mice
(A) Confocal images of heart showing the binding of FITC-labeled tomato lectin and a goat antibody against mouse LPL. Both the tomato lectin and the
LPL-specific antibody were injected intravenously into a wild-type mouse and a Gpihbp1/ mouse. Three minutes later, mice were perfused extensively
with PBS and then perfusion fixed with 3% PFA. The scale bars represent a distance of 50 mm.
(B) Confocal microscopy showing the binding of CD31-, GPIHBP1-, and LPL-specific antibodies to brown adipose tissue of a wild-typemouse and aGpihbp1/
mouse. Images were taken with a 1003 objective without optical zoom or with 43 optical zoom. To visualize both the apical and basolateral surfaces of
capillaries, cross-sections of capillaries that cut through an endothelial cell nucleus (blue) were identified (boxed areas) and viewed at high magnification.
GPIHBP1 (purple), LPL (red), and CD31 (green) were all expressed at the apical and basolateral surfaces of endothelial cells in wild-type mice, but no LPL
was present on the apical (lumenal) surface of the capillary endothelium inGpihbp1/mice. The scale bar represents a distance of 2.5 mm. (See also Figure S5.)
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That LPL is synthesized by adipocytes and myocytes but hydro-
lyzes triglycerides of lipoproteins within capillaries has been
known for decades (Cryer et al., 1976; Havel and Kane, 2001).
Precisely how LPL finds its way into capillaries, however, has
been a mystery. In the current study, we provide evidence that
GPIHBP1 is essential for LPL entry into capillaries. First,we found
that LPL is mislocalized away from capillaries in the absence of
GPIHBP1. GPIHBP1 is expressed exclusively in capillary endo-
thelial cells, and in tissue sections of wild-type mice, most of
the LPL colocalizes with GPIHBP1. In Gpihbp1/ mice, most
of the LPL is found on the outside of parenchymal cells, colocal-
izing with collagen IV (in the case of brown adipose tissue) or
b-dystroglycanor laminin (in thecaseof skeletalmuscleandheart
tissue). Second, we found that GPIHBP1 is present on both the
basolateral and the apical surfaces of endothelial cells, both in
cultured cells and in vivo within the capillaries of brown adipose
tissue. Third, we show that the expression of GPIHBP1 in endo-thelial cells confers the ability to transport LPL and a GPIHBP1-
specific monoclonal antibody from the basolateral to the apical
surface of cells. This transport could be blockedby addingPIPLC
to the basolateral chamber (an intervention that releases
GPIHBP1 from the surface of cells). Also, the transport of LPL,
but not the transport of antibody11A12,wasblockedbymutating
the long stretch of negatively charged amino acids within
GPIHBP1’s acidic domain.Mutating the acidic domain eliminates
the ability of GPIHBP1 to bind LPL but has no effect on the
epitope for antibody 11A12 (Beigneux et al., 2009b). Fourth, we
show that GPIHBP1 transports a GPIHBP1-specific monoclonal
antibody across endothelial cells in vivo. Finally, we show that
LPL is absent from the capillary lumen in Gpihbp1/ mice. All
of these findings point to a direct role for GPIHBP1 in transporting
LPL from the interstitial spaces to the lumen of capillaries.
Our current studies explain enigmatic findings from earlier
studies. First, the striking phenotype ofGpihbp1/mice, severe
hypertriglyceridemia (Beigneux et al., 2007), which was initially
puzzling, can now be more clearly understood. With little or noCell Metabolism 12, 42–52, July 7, 2010 ª2010 Elsevier Inc. 49
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ing of triglyceride-rich lipoproteins cannot occur. Second, our
findings help to explain the abnormal kinetics of LPL release in
Gpihbp1/ mice after an injection of heparin. Weinstein et al.
(2008) found that the release of LPL into the plasma of
Gpihbp1/ mice is delayed after a bolus of heparin, while LPL
release is rapid in wild-type mice. In the current studies, we
showed that LPL in Gpihbp1/ mice is located in close prox-
imity to parenchymal cells, whereas it is largely associated
with capillaries in wild-type mice. When LPL is located in capil-
laries, it makes sense that an intravenous bolus of heparin would
release LPL quickly. In the case of Gpihbp1/ mice, it presum-
ably takes longer for the heparin to reach the interstitial spaces
and release that pool of LPL. Third, our findings provide an
explanation for the normal LPL mass and activity measurements
in Gpihbp1/ mice. By immunohistochemistry, we found sub-
stantial amounts of LPL in the tissues of Gpihbp1/ mice, but
it was strikingly mislocalized.
Very recently, mutations in GPIHBP1 have been identified in
humans with severe hypertriglyceridemia (Beigneux et al.,
2009a; Franssen et al., 2010; Olivecrona et al., 2010; Wang
and Hegele, 2007). All are missense mutations involving highly
conserved amino acid residues within GPIHBP1’s Ly6 domain.
Functional studies on the mutant proteins have revealed that
the mutations result in a loss of GPIHBP1’s capacity to bind LPL.
The exact mechanism by which GPIHBP1 transports LPL
across endothelial cells is not clear. Given the known association
of GPI-anchored proteins with caveolae (Brown and Rose, 1992;
Nosjean et al., 1997; Rajendran and Simons, 2005; Varma and
Mayor, 1998) and the abundance of caveolae in endothelial cells
(Anderson, 1993), one possibility is that LPL is transported by
caveolar-dependent transcytosis. This possibility needs to be
investigated thoroughly.
Our immunochemical studies of GPIHBP1 were made pos-
sible by a new monoclonal antibody against mouse GPIHBP1,
11A12 (Beigneux et al., 2009b). Antibody 11A12 binds avidly to
GPIHBP1 in conventional immunohistochemistry studies and
when injected intravenously into mice; these experiments re-
vealed that GPIHBP1 is restricted to capillary endothelial cells
and is absent in larger vessels. Our studies of LPL localization
were aided by two antibodies against LPL, one generated
against native bovine LPL and the other against a recombinant
mouse LPL fragment; both antibodies were specific for LPL as
judged by western blots and immunohistochemical studies
with Lpl knockout mice. Both antibodies worked well in immuno-
histochemical studies, detecting LPL in parenchymal cells and in
capillary endothelial cells (but not larger vessels), colocalizing
with GPIHBP1. The availability of these antibodies provides
for new approaches to investigate mislocalization of LPL
away from capillaries as a potential explanation for hypertrigly-
ceridemia.
The ability to visualize GPIHBP1 and LPL on the lumenal
surface of capillaries and the ability to assess transport from
the interstitial space to the capillary could open the door to a
better understanding of hypertriglyceridemia. For many years,
scientists interested in hypertriglyceridemia have focused on
measuring LPL levels 15 min after an injection of heparin, LPL
levels in tissue extracts, and LPL mRNA levels. Unfortunately,
there is little reason to believe that these measurements provide50 Cell Metabolism 12, 42–52, July 7, 2010 ª2010 Elsevier Inc.an accurate representation of the amount of LPL in capillaries.
Indeed, in the case ofGpihbp1/mice, none of those measure-
ments provided insights into the mechanism of hyperlipidemia.
The phenotype of Gpihbp1/ mice only made sense with the
realization that GPIHBP1 functions as a transporter and that no
LPL is present in the lumens of capillaries of those mice. We
speculate that assessing intracapillary LPL levels could prove
to be worthwhile in other forms of hypertriglyceridemia, aside
from those caused by specific structural abnormalities in
GPIHBP1.
In humans, mechanisms for severe cases of hypercholesterol-
emia have come into focus (Goldstein et al., 1985, 2001; Horton
et al., 2009), but the same cannot be said for many cases of
severe hypertriglyceridemia. Many patients with severe hypertri-
glyceridemia have no mutations in LPL, GPIHBP1, APOCII, or
APOAV and no obvious explanation for their disease (Beigneux
et al., 2009a; Wang and Hegele, 2007). For some patients with
hypertriglyceridemia, there are no obvious abnormalities in tissue
stores of LPL or levels of LPL in the postheparin plasma—a situ-
ation reminiscent of Gpihbp1/ mice. Thus, it seems possible
that defective transport of LPL into the lumen of capillaries could
underlie at least some cases of hypertriglyceridemia in humans.
A structurally intact GPIHBP1 is a cornerstone of this transport,
but we suspect that other proteins participate in this process.
Elucidating those factors might represent a productive area for
future research.
EXPERIMENTAL PROCEDURES
Mice
Gpihbp1/ and L0-MCK mice (Lpl-deficient mice expressing hLPL from a
muscle-specific promoter [MCK]) have been described previously (Beigneux
et al., 2007; Weinstock et al., 1997). Mice were fed a chow diet and housed
in a barrier facility with a 12 hr light-dark cycle. All studies were approved by
UCLA’s Animal Research Committee.
Antibodies, Immunohistochemistry, and Antibody Injection
Experiments
A rat monoclonal antibody against mouse GPIHBP1 (11A12) has been
described previously (Beigneux et al., 2009b). In some experiments, antibody
11A12 was coupled to fluorescent dye Alexa 555 (Invitrogen; Carlsbad, CA) or
infrared dye IR800 (LI-COR; Lincoln, NE). We also used a chicken antibody
against bovine LPL (Olivecrona and Bengtsson, 1983) and a goat antibody
against a recombinant mouse LPL fragment produced in Escherichia coli
(Weinstein et al., 2008). The specificity of the LPL-specific antibodies was
assessed by western blot and by immunocytochemistry (see Supplemental
Experimental Procedures).
To detect GPIHBP1 in mouse tissues, 8–10 mm-thick frozen sections were
prepared and incubated with primary antibodies (3 mg/ml for monoclonal
antibody 11A12, 1:400 for the hamster anti-CD31 antibody [Millipore; Billerica,
MA], 1:200 for the rabbit anti-b-dystroglycan antibody [Santa Cruz Biotech-
nology; Santa Cruz, CA], 1:1000 for the rabbit anti-collagen type IV antibody
[Cosmo Bio USA; Carlsbad, CA], 1:160 for the rabbit anti-laminin antibody
[Millipore], 7 mg/ml for the chicken anti-bovine LPL antibody, and 10 mg/ml
for the goat anti-mouse LPL antibody). Secondary antibodies (Alexa 555- or
Alexa 649-labeled anti-rat IgG, Alexa 488- or Alexa 649-labeled anti-hamster
IgG, Alexa 488- or Alexa 649-labeled anti-rabbit IgG, Alexa 546-labeled anti-
chicken IgG, and Alexa 549- or Alexa 488-labeled anti-goat IgG) were used
at a dilution of 1:200 and were incubated with slides at room temperature
(RT) for 1 hr. Images were obtained with an Axiovert 200 MOT microscope
equipped with an Apotome (both from Zeiss; Oberkochen, Germany) or by
confocal fluorescence microscopy with a Leica SP2 1P-FCS microscope
(Heidelberg, Germany) as described in the Supplemental Experimental
Procedures.
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GPIHBP1- or 200 mg LPL-specific antibodies in a volume of 0.1 ml. After
3 min, mice were perfused with 10 ml PBS (2–3 ml/min) through the left
ventricle followed by 10 ml of 3% PFA in PBS. The tissues were embedded
in optimal cutting temperature (OCT) compound and processed for immuno-
histochemistry.
For in vivo antibody transport experiments, one quadriceps muscle of wild-
type and Gpihbp1/ mice was injected intramuscularly with 10 ml normal
saline containing 15 mg each of the rat anti-GPIHBP1 antibody 11A12 and
nonimmune rabbit IgG. After 30 min, the mice were injected intravenously
with 200 mg each of Alexa 488-labeled goat anti-rabbit IgG and Alexa 568-
labeled goat anti-rat IgG. Three minutes later, the mice were perfused with
PBS and tissues were fixed in situ with 3% PFA. The tissues were embedded
in OCT and processed for immunohistochemistry.
Production of GPIHBP1-Expressing Endothelial Cell Lines
RHMVECs and bovine aortic endothelial cells were obtained from VEC
Technologies (Rensselaer, NY) and grown in MCDB-131 complete medium
with antibiotics. The coding sequences for an S-protein-tagged GPIHBP1
(Beigneux et al., 2007) were cloned into the lentiviral vector pRRL-cPPT-
MCS-IRES as described in the Supplemental Experimental Procedures. A
lentivirus for an S-protein-tagged mouse GPIHBP1 mutant (D,E(24–48)A) in
which all of the aspartates and glutamates between residues 24 and 48
were replaced with alanine (EDGDADPEPENYNYDDDDDEEEEEE to AAGAAA
PAPANYNYAAAAAAAAAAA) was created by site-directed mutagenesis with
Phusion mutagenesis (Finnzymes; Espoo, Finland).
To assess levels of Gpihbp1 expression, total RNA was prepared from
mouse tissues with TRI Reagent (Sigma; St. Louis) and from transduced cells
with the RNeasy Kit (QIAGEN; Valencia, CA). RNA was treated with DNase I
(Ambion; Austin, TX) and reverse transcribed into cDNA with a mixture of
random primers, oligo(dT), and SuperScript III (Invitrogen). Primers 50-AG-
CAGGGACAGAGCACCTCT-30 and 50-AGACGAGCGTGATGCAGAAG-30
were used to amplify the mouseGpihbp1 cDNA, and primers 50-CAGCGAGAT
CCTGAGGGTCA-30 and 50-TCCCCTCTTTCACAGAGCACC-30 were used to
amplify mouse and rat Cd31 cDNAs. PCR reactions were performed in tripli-
cate on a 7900HT Fast Real-Time PCR system (Applied Biosystems; Foster
City, CA). Gene expression levels were calculated with the comparative cycle
threshold (CT) method.
Production of LPL for LPL Transport Assays
hLPL was concentrated from the medium of a CHO cell line stably expressing
V5-tagged hLPL (a gift fromMark Doolittle, UCLA) (Beigneux et al., 2009b). The
production of bovine LPL is described in the Supplemental Experimental
Procedures.
Endothelial Cell-Based Assays of LPL Transport
Endothelial cells were grown on Millicell filters (polyethylene terephthalate,
1.1 cm2 filtration area, 1 mm pore size; Millipore) that had been coated with
fibronectin (BD Biosciences; San Jose, CA). Cells were grown until they
formed tight monolayers as judged by electrical resistance (tested with a Milli-
cell Electrical Resistance System; Millipore) or by observing water tightness
over 24 hr. For each assay, monolayers were monitored for leakage by
observing the transport of either an irrelevant antibody (IRDye680-labeled
donkey anti-goat IgG; LI-COR) or BSA (1 mg/ml; Amresco; Solon, OH).
For antibody transport assays, IRDye800-labeled antibody 11A12 and an
IRDye680-labeled donkey anti-goat IgG antibody (LI-COR) were added to
the bottom (basolateral) chamber in PBS at a concentration of 0.25 mg/ml. After
incubating the cells for the specified times at 37C, 1 U/ml of PIPLCwas added
to the apical chamber to release GPIHBP1. Antibody in apical and basolateral
media was detected by dot blotting or western blots (Supplemental Experi-
mental Procedures).
For LPL transport assays, human or bovine LPL (hLPL or bLPL, respectively)
was added to the basolateral chamber and PBS was added to the apical
chamber. Cells were incubated at 37C for 1 hr and treated with either heparin
(100 U/ml for 15 min at RT; APP Pharmaceuticals; Schaumburg, IL) or PIPLC
(2.5 U/ml for 30 min at 37C) to release LPL from the cell surface. Apical and
basolateral samples were then collected, and relative amounts of LPLwere as-sessed by dot blotting, western blots, or an ELISA (Supplemental Experimental
Procedures).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, and five figures and can be found with this article
online at doi:10.1016/j.cmet.2010.04.016.
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